Baby formula company Bubs Australia (ASX: BUB) has all but closed the chapter on its financial and legal troubles that underlined most of last year. In the USA, its weekly scan revenue exceeded $1.5 million per week, with over 24,000 tins sold. The number of tins sold increased by 10k to about 24k compared to
Read More
Baby formula and food company Bubs Australia (ASX: BUB) spent a large part of FY23 undertaking reputation management as its dirty laundry was hung for the world to see. Boardroom disputes, miffed shareholders, lawsuits, and a CEO ousting—the Company had to work in overdrive to maintain shareholder confidence. The impact of its decisions can be
Read More
Just a month after Bubs Australia (ASX: BUB) announced that executive chairman Dennis Lin would be removed from the business, the baby milk formula company announced another shake up of its executive line up. Perhaps a foreseeable one, this time founder and CEO Kristy Carr was terminated from her position with immediate effect due to
Read More
The FDA has deferred further consideration of one of Australia’s top dairy producers A2 Milk’s (ASX: A2M) request to import infant milk formula (IMF) into the United States. Though the application has not been rejected, it is also not close to being approved. Since February 2022, the US has been facing an acute shortage of
Read More
It’s hard to believe that in 2022 food security in America would be an issue, but for thousands of parents, feeding their babies is a daily struggle. The US baby formula crisis was the perfect storm of a monopolised market, a serious food recall and a sloppy government response. The story in a nutshell? Major
Read More
It’s the most talked about stock in the retail investor community right now, and having climbed 61.84% in the past month it may be for a while yet. I’m talking about Bubs (ASX: BUB), the company coming to the rescue of US parents who are the unfortunate victims of the US formula crisis. The serious
Read More